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[~  Functional interaction between CFTR and the renal sodium- 
phosphate cotransporter (NPT Ila) 
N. Bakouh 1, R Hulin 1 , F. Makaci 1 , D. Pri~ 2, B. Cherif-Zahar 1 , A. Edelman 1 , 
G. Planelles 1 . 11NSERM U 806, 2INSERM U 811, France 
The physiological role of CFTR in the renal epithelium is not known. In the proximal 
tubule, CFTR co-localizes with the sodium-phosphate cotransporter NPT IIa, a 
protein involved in phosphate (Pi) reabsorption. The aim of our work is to determine 
if there is a functional interaction between CFTR and NPT IIa. To this end, the 
mRNA coding for these proteins were injected in Xenopus laevis oocytes. Three 
days later, currents induced by 1 gM forskolin (Iforsk) and/or by 1 mM Pi (Ipi) were 
measured in voltage-clamped (50mV)  oocytes expressing NPT IIa alone, CFTR 
alone, or in oocytes co-expressing CFTR + NPT IIa. 
Results: In oocytes expressing CFTR alone, Ifors k 406.2±29.5nA (n 16). Ipi 
measured after CFTR activation (using 1 gM forskolin) is significantly decreased 
in CFTR + NPT IIa co-expressing oocytes. Same result was obtained when Ipi was 
measured before CFTR activation: Ipi decreased from 59.1±6.1nA, n 7 in 
oocytes expressing NaP IIa alone to 37.0±4.8 nA, n 5, in oocytes co-expressing 
CFTR + NPT IIa. These results show that Ipi reduction is not due to an increase 
in cAMR and are in agreement with an interaction NPT IIa-CFTR. 
Coneluslon: Our study suggests that, after expression in Xenopus laevis oocytes, 
CFTR interacts functionally with NPT IIa. At present ime, it is not known if 
expressing CFTR alters the activity and/or the membrane xpression of NPT IIa. 
To clarify this, we are now performing kinetic measurements of NPTIIa activity, 
and analyzing the membrane expression of NPTIIa and CFTR in oocytes expressing 
only one of these proteins, or co-expressing both. A possible molecular interaction 
between CFTR and NPT IIa will be studied using co-immunoprecipitation assay. 
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~]  Sodium 4-phenylbutyrate increases CFTR function but also 
enhances ENaC expression and function in human nasal 
epithelial cells 
V Pruli~re-Escabasse 1'2,C. Plan~s 3, R Fanen 4, S.A. Coste 1'2, E. Escudier 1, 
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4-phenylbutyrate (4-PBA) has been proposed to treat CF patients with AF508 
mutation. Indeed, 4-PBA was reported to increase the mutant CFTR expression 
into the cell membrane with a restoration of the chloride secretion in a bronchial 
cell line with AF508 mutation and to improve nasal ddp of AF508 patients. However, 
any study has evaluated the impact of 4-PBA on ENaC whose upregulation largely 
participate to CF disease. The objective of this study was to examine the effects 
of 4-PBA on the expression and function of ENaC in primary cultures from 
nasal epithelial cells (HNEC) from non-CF and one CF patient. Short circuit 
current experiments showed that 4-PBA (5 mM for 6 h) enhanced cAMP dependent 
current but also apical amiloride-sensitive Na transport in non CF and CF patients. 
At protein level, 4-PBA increased the apical membrane surface expression of 
~,, [3, 7-ENaC protein without change in total ~,, [3 and 7-ENaC protein levels in 
CF and non CF HNEC. Brefeldin A, a blocker of anterograde transport prevented 
4PBA-induced increase of ~,, [3 and 7-ENaC subunits into the apical membrane. 
Moreover, 4-PBA did not change the internalization of the three subunits evaluated 
from biotinylation~lebiotinylation experiments. 
In conclusion, 4-PBA enhances Na transport by increasing the translocation of 
~,, [3 and 7-ENaC subunits from cytoplasm to the apical membrane in HNEC from 
non-CF and CF patients. These results highlight hat 4-PBA should be used with 
caution to treat CF patients whose ENaC function is upregulated by the loss of 
CFTR negative control. 
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The AF508CFTR mutation results in a mutant protein that fails to progress 
to the apical membrane, where it functions as a cAMP-regulated C1 channel. 
However, C1 channel activity can be detected at the plasma membrane when 
AF508 CFTR is overexpressed, synthesized at a reduced temperature, or in the 
presence of chemical chaperones. Thus, strategies that facilitate the translocation 
of AF508CFTR to the plasma membrane may be beneficial for the treatment of 
CE Peroxisome proliferator activated receptors (PPARs) exist in three subtypes: 
~,, [3 and 7, and are involved in orchestrating gene expression in response to 
nutritional, pharmacological and metabolic stimuli. PPAR7 is activated by butyrate, 
which also promotes AF508CFTR trafficking. Moreover, PPAR7 activation reduces 
inflammation in many cell types. Thus, PPAR7 could represent an attractive 
target for CF therapy, by simultaneously upregulating AF508CFTR trafficking and 
downregulating inflammation. We report here that treatment of cells expressing 
AF508 CFTR with pioglitazone resulted in the appearance of functional cAMP- 
stimulated C1 channel activity at the cell surface. PPAR7 agonists also restored 
cAMP-mediated CFTR C1 channel activity in CF airway epithelial cells, cells 
expressing recombinant AF508 CFTR, and in colonic epithelium of CF mice. CFTR 
promoter analyses and real time PCR revealed that thiazolidinediones increased 
transcription of CFTR mRNA, and the amount of AF508CFTR in the plasma 
membrane. The present study demonstrates that selected PPAR7 ligands may be 
efficacious for the treatment of CE 
[•] Butyrate affects ENaC expression and sodium absorption in 
colonic epithelial cells 
C. Iordache, M. Duszyk. Department of Physiology, University of Alberta, 
Edmonton, Alberta, Canada 
The short-chain fatty acid sodium butyrate was suggested that it may be a useful 
therapeutic agent for treatment of CF in individuals expressing AF508CFTR. This 
agent partially restored cAMP-activated C1 secretion by stimulating AF508CFTR 
gene expression and increasing the amount of AF508CFTR protein in the plasma 
membrane. However, butyrate has numerous and diverse effects on cellular phys- 
iology including modulation of protein kinase and phosphatase activities and 
transcriptional ctivation of numerous gene products. In this study we examined 
the effects of butyrate on the transepithelial nion secretion in colonic epithelial 
cells. Under standard cell culture conditions, T84 cells did not exhibit amiloride- 
sensitive short circuit current (Isc). However, incubation of cells with butyrate 
produced time-dependent appearance of amiloride sensitive Isc, with the maximal 
response occurring between 24 and 48 hours. Quantitative PCR and western 
blot studies indicated that butyrate potently stimulated ENaC7 subunit expression, 
having relatively small effect on the ~, subunit and no effect on the [3 subunit. 
The effect of butyrate could be mimicked by trichostatin A, a specific inhibitor of 
histone deacetylase. These results suggest, hough do not directly demonstrate, that 
butyrate may be affecting ENaC by inhibiting histone deacetylase. This action of 
butyrate is likely to occur in vivo because germ free mice, which have reduced 
butyrate level in the colon, had lower ENaC expression and sodium absorption 
than control mice. This observation has potential implications for the clinical use 
of butyrate in vivo. Butyrate-induced upregulation of ENaC expression may in fact 
compromise CFTR function in colonic epithelia. 
